694495-63-1

Basic information

• Product Name: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE
• Synonyms: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE;N-(4-METHYL-3-PYRIDINYL)-CARBAMIC ACID, METHYL ESTER;Methyl N-(4-methylpyridin-3-yl)carbamate;CarbaMic acid, N-(4-Methyl-3-pyridinyl)-, Methyl ester;Methyl (4-Methylpyridin-3-yl)carbaMate;Carbamic acid, (4-methyl-3-pyridinyl)-, methyl ester;Tofacitinib Impurity 52;Methyl (4-methyl-3-pyridinyl)carbamate
• CAS NO: 694495-63-1
• Molecular Formula: C₈H₁₀N₂O₂
• Molecular Weight: 166.1772
• Mol File: 694495-63-1.mol
• Article Data: 9

Chemical Properties

• Melting Point: 117～118℃
• Boiling Point: 227.812°C at 760 mmHg
• Flash Point: 91.578°C
• Appearance: /
• Density: 1.201g/cm³
• Vapor Pressure: 0.076mmHg at 25°C
• Refractive Index: 1.567
• PKA: 12.94±0.70(Predicted)
• CAS DataBase Reference: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE(694495-63-1)
• EPA Substance Registry System: 3-METHOXYCARBONYLAMINO-4-METHYLPYRIDINE(694495-63-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 694495-63-1(Hazardous Substances Data)

Usage

Uses

Methyl 4-Methylpyridin-3-ylcarbamate can be used as JAK3 inhibitors for its immunosuppressant properties.

InChI:InChI=1/C8H10N2O2/c1-6-3-4-9-5-7(6)10-8(11)12-2/h3-5H,1-2H3,(H,10,11)

Upstream product

• 3430-27-1 3-amino-4-methylpyridine 
• 616-38-6 carbonic acid dimethyl ester 
• 79-22-1 methyl chloroformate 

Downstream Products

• 1204176-45-3 3-methoxycarbonylamino-4-methylpiperidine 
• 1204176-45-3 cis-3-methoxycarbonylamino-4-methylpiperidine 
• 1354621-59-2 cis-N-benzyl-3-methoxycarbonylamino-4-methylpiperidine 
• 1228879-37-5 cis-N-benzyl-3-methoxycarbonylamino-4-methylpiperidine bis(hydrochloride) 
• 1204176-45-3 cis-methyl (4-methylpyridin-3-yl)carbamate 
• 1615709-89-1 1-benzyl-4-methyl-3-(methylamino)pyridinium bromide 
• 77862-24-9 4-Methyl-3-(methylamino)pyridine 
• 1354621-59-2 cis-N-benzyl-3-methylamino-4-methylpiperidine 
• 1204176-45-3 methyl-(4-methylpiperidin-3-yI)carbamate 
• 540737-29-9 tofacitinib hemi-citrate 
• 540737-29-9 Tofacitinib citrate 
• 1259404-17-5 tasocitinib 
• 477600-74-1 tert-butyl (3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidine-1-carboxylate 

Relevant articles and documents

A synthetic cis - 1 - benzyl - 3 - methylamino - 4 - methyl - piperidine

The invention relates to a method for synthesizing cis-1-benzyl-3-methylamino-4-methyl-piperidine, in particular to a method for synthesizing cis-1-benzyl-3-methylamino-4-methyl-piperidine by taking 1-benzyl-3-methylamino-4-methyl-piperidine bromide as an

Design and synthesis of tricyclic jak3 inhibitors with picomolar affinities as novel molecular probes

The Janus kinase (JAK) signaling pathway is of particular importance in the pathology of inflammatory diseases and oncological disorders, and the inhibition of Janus kinase 3 (JAK3) with small molecules has proven to provide therapeutic immunosuppression. A novel class of tricyclic JAK inhibitors derived from the 3-methyl-1,6-dihydrodipyrrolo[2,3-b:2',3'-d]pyridine scaffold was designed based on the tofacitinib-JAK3 crystal structure by applying a rigidization approach. A convenient synthetic strategy to access the scaffold via an intramolecular Heck reaction was developed, and a small library of inhibitors was prepared and characterized using in vitro biochemical as well as cellular assays. IC50 values as low as 220 pm could be achieved with selectivity for JAK3 over other JAK family members. Both activity and selectivity were confirmed in a cellular STAT phosphorylation assay, providing also first-time data for tofacitinib. Our novel inhibitors may serve as tool compounds and useful probes to explore the role of JAK3 inhibition in pharmacodynamics studies.

HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS

The invention provides compounds of formula (I) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula (I).